Key result
Platelet hyperaggregation linked to ~13-fold higher cardiovascular event risk in CAD, driven by CYP2C19 polymorphisms.
Why the study?
Does CYP2C19 polymorphism increase the risk of cardiovascular events in Indonesian patients with stable CAD treated with clopidogrel?
Population
69 Indonesian patients with stable coronary artery disease treated with clopidogrel
Comparison
Presence of CYP2C19 polymorphism vs Wild type CYP2C19 (*1/*1)
Design
Cohort
Follow-up
6 months
Authors
Loading...
May warrant caution with standard clopidogrel dosing in Indonesian CYP2C19 carriers; leaves open need for genotype-guided trials before practice change.
Cohort (n=69)
Yes
Does CYP2C19 polymorphism increase the risk of cardiovascular events in Indonesian patients with stable CAD treated with clopidogrel?
Effect estimate: OR 13.250
p-value: p=0.030
In Indonesian patients with stable CAD on clopidogrel, CYP2C19 variant alleles are associated with platelet hyperaggregation and an increased risk of cardiovascular events.
Amir et al. (2017) conducted a cohort in Coronary Artery Disease (n=69). CYP2C19 polymorphism (*2 or *3 variant alleles) vs. CYP2C19 wild type (*1/*1) was evaluated on Cardiovascular events (acute myocardial infarction, ischemic stroke, or cardiovascular death) (OR 13.250, p=0.030). Platelet hyperaggregation, which was more common in patients with CYP2C19 polymorphisms, was associated with a significantly increased risk of cardiovascular events (OR 13.250) in Indonesian patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: